Psyence Biomed Advances Phase IIb Clinical Trial Progress
Exciting developments are underway at Psyence Biomedical Ltd. (Nasdaq: PBM) as they focus on their active Phase IIb clinical trial testing nature-derived psilocybin combined with psychotherapy. This study aims to assess the efficacy of psilocybin as a treatment for Adjustment Disorder that can follow a life-limiting cancer diagnosis, particularly in a palliative care environment.
Patient Recruitment and Therapy Training Takes Shape
Two trial locations have been activated in Australia, namely Vitalis and EMPAX, and patient screening processes have been initiated. Psyence Biomed is enthusiastic about randomizing the first patients into its study shortly after the new year. Alongside patient recruitment, therapist training is also being actively conducted at these sites to ensure readiness.
Collaboration for Effective Outreach
To enhance patient enrollment efforts, Psyence Biomed has enlisted the help of a contract research organization, iNGEN? CRO, which has partnered with the Australian Clinical Trial Network (ACTioN) for recruitment strategies. This team is utilizing various channels, including social media and email outreach to physicians, potential clinical trial locations, and advocacy groups in the fields of oncology, primary care, and psychiatry.
Expectations for Recruitment and Results
Dr. Clive Ward-Able, Medical Director of Psyence Biomed, remarked on the substantial strides made in starting the trial's activities. He expressed optimism that randomization and treatments would commence soon after the holiday season. With the dedicated efforts from ACTioN's team, he believes that patient recruitment will proceed efficiently.
ACTioN's Role in Patient Engagement
David Harford, Managing Director of ACTioN, highlighted the significance of their collaboration with Psyence Biomed. ACTioN's mission aligns with supporting innovative research such as that being conducted by Psyence on psilocybin and its potential benefits for patients dealing with Adjustment Disorder in palliative care. Their focus on recruitment strategies is essential for the success of the study.
About Psyence Biomed
Psyence Biomedical Ltd. is a pioneering biotechnology company dedicated to developing nature-derived psilocybin-based medicines aimed at addressing mental health disorders within palliative care settings. Now publicly traded on Nasdaq under the ticker PBM, the company aims to highlight the evidence-based approaches to creating safe and effective psychedelic therapeutics. "Psyence" reflects their commitment to merging psychedelics with scientific innovation for better mental health solutions.
Contact Information
For further inquiries about Psyence Biomed, individuals are encouraged to reach out via email: ir@psyencebiomed.com, or for media, contact media@psyencebiomed.com. General inquiries can be made to info@psyencebiomed.com. For direct phone contact, reach out at +1 416-477-1708.
Frequently Asked Questions
What is the focus of Psyence Biomed's clinical trial?
The clinical trial focuses on evaluating nature-derived psilocybin as a treatment for Adjustment Disorder within palliative care settings.
When will the first patients be randomized in the trial?
Psyence Biomed anticipates that the first patients will be randomized into the study shortly after January.
Who is responsible for patient recruitment in the trial?
The Australian Clinical Trial Network (ACTioN) has been engaged to implement patient recruitment strategies alongside Psyence Biomed's efforts.
What is the name of Psyence Biomed's contract research organization?
Psyence Biomed's contract research organization is iNGEN? CRO, which is assisting with patient recruitment for the trial.
What is Psyence Biomed's mission?
Psyence Biomed is dedicated to developing innovative, nature-derived psychedelic medicines to address mental health disorders.
